市場調査レポート

商品コード

1344292

医薬品ドラッグデリバリー市場：投与経路別、用途別：世界の機会分析と産業予測、2023-2032年

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年06月01日
発行: Allied Market Research
ページ情報: 英文 236 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,730 838,413円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,404,672円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.32円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

医薬品ドラッグデリバリー市場は2022年に1兆4,987億2,000万米ドルとなり、2023年から2032年までのCAGRは4.4%で、2032年には2兆3,072億7,000万米ドルに達すると推定されています。

Pharmaceutical Drug Delivery Market-IMG1

心血管疾患、糖尿病、がん、呼吸器疾患などの慢性疾患は、長期にわたる投薬治療が特徴です。これらの疾患では、症状を抑えたり、疾患の進行を遅らせたり、生活の質を維持するために、定期的な薬剤投与が必要となります。このため、効果的なドラッグデリバリーシステムに対する需要が高まっており、市場成長の原動力となっています。国際糖尿病連合（IDF）によると、2021年には、成人の糖尿病患者の約4人に3人が低・中所得国に住み、西太平洋では約2億600万人が糖尿病と診断されたと推定されています。

例えば、2022年5月、米国食品医薬品局（FDA）は、2型糖尿病を治療するための新しい注射デリバリー製品であるMounjaroを承認しました。このように、糖尿病の有病率の増加は、糖尿病の治療に非常に効果的な高度なインスリン送達システムの開発につながっています。さらに、心血管障害、関節炎、神経変性疾患、骨粗鬆症などの加齢関連疾患の有病率の増加が、効果的なドラッグデリバリーに対する大きな需要を生み出しています。

例えば、2023年1月、製薬業界の世界的リーダーであるバイオジェン社は、アルツハイマー病治療薬LEQEMBIの米国食品医薬品局（FDA）承認を取得しました。LEQEMBIは、アルツハイマー病を効果的に治療するモノクローナル抗体指向性の静脈内ドラッグデリバリー薬です。このように、新たな標的ドラッグデリバリーや放出制御製剤の開拓は、市場の成長にさらに貢献します。しかし、厳しい規制要件は、新しいドラッグデリバリー技術の時間、コスト、複雑さを増大させ、市場の成長を抑制する可能性があります。さらに、新しいドラッグデリバリーの研究開発に関連する高コストは、市場成長にマイナスの影響を与えます。

一方、高度なドラッグデリバリーシステムに対する需要の増加は、予測期間中に市場成長の有利な機会を生み出すと予想されます。これは、慢性疾患の有病率の増加、治療成績の向上、先進ドラッグデリバリーシステムの開発に有利な償還政策が利用可能であることに起因しています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競合の激しさ
市場力学
- 促進要因
  - 様々な慢性疾患の増加
  - ドラッグデリバリーシステムの技術進歩
- 抑制要因
  - ドラッグデリバリーの承認に関する厳しい規制要件
- 機会
  - 高度な送達システムに対する需要の増加
COVID-19市場への影響分析

第4章医薬品ドラッグデリバリー市場：投与経路別

概要
経口ドラッグデリバリー
経鼻ドラッグデリバリー
経眼ドラッグデリバリー
局所ドラッグデリバリー
その他のドラッグデリバリー

第5章医薬品ドラッグデリバリー市場：用途別

概要
がん
糖尿病
心血管疾患
その他

第6章医薬品ドラッグデリバリー市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他アジア太平洋地域
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他の地域

第7章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第8章企業プロファイル

F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Bayer AG
Cipla Ltd
Amgen Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 02. PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 03. PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 04. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 05. PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 06. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2022-2032 ($BILLION)
TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2022-2032 ($BILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($BILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($BILLION)
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 15. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 16. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 17. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 19. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 24. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 26. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 27. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 29. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 30. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 32. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 34. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 35. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 36. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 37. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 38. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 39. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 40. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 41. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 42. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 43. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 44. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 45. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 46. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 47. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 48. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 49. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 50. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 51. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 52. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 53. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 54. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 55. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 56. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 57. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 58. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 59. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 60. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 61. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 62. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 63. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 64. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 65. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 66. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 67. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 68. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 69. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 70. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 71. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 72. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 73. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 74. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 75. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 76. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 77. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 78. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 79. NOVARTIS AG: KEY EXECUTIVES
TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 83. NOVARTIS AG: KEY STRATERGIES
TABLE 84. PFIZER INC.: KEY EXECUTIVES
TABLE 85. PFIZER INC.: COMPANY SNAPSHOT
TABLE 86. PFIZER INC.: PRODUCT SEGMENTS
TABLE 87. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 88. SANOFI S.A.: KEY EXECUTIVES
TABLE 89. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 90. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 91. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 92. BAYER AG: KEY EXECUTIVES
TABLE 93. BAYER AG: COMPANY SNAPSHOT
TABLE 94. BAYER AG: PRODUCT SEGMENTS
TABLE 95. BAYER AG: PRODUCT PORTFOLIO
TABLE 96. CIPLA LTD: KEY EXECUTIVES
TABLE 97. CIPLA LTD: COMPANY SNAPSHOT
TABLE 98. CIPLA LTD: PRODUCT SEGMENTS
TABLE 99. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 100. AMGEN INC.: KEY EXECUTIVES
TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN PHARMACEUTICAL DRUG DELIVERY MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 10. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. PHARMACEUTICAL DRUG DELIVERY MARKET BY REGION, 2022
FIGURE 22. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 23. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 24. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 28. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 29. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 30. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 31. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 32. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 33. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 34. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 35. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 36. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 37. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 38. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 39. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 40. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 72. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A06102

According to a new report published by Allied Market Research, titled, "Pharmaceutical Drug Delivery Market," The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are: Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

Topical drug delivery
Other drug delivery
Oral drug delivery
Nasal drug delivery
Ocular drug delivery

By Application

Cancer
Diabetes
Cardiovascular Diseases
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Amgen Inc.
Bayer AG
Cipla Ltd
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of various chronic diseases
  - 3.4.1.2. Technological advancement in drug delivery systems

3.4.2. Restraints
- 3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery

3.4.3. Opportunities
- 3.4.3.1. Increase in demand for advanced delivery systems

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Oral drug delivery
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Nasal drug delivery
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Ocular drug delivery
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Topical drug delivery
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Other drug delivery
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Cardiovascular Diseases
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Route of Administration
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Key market trends, growth factors and opportunities
  - 6.2.4.1.2. Market size and forecast, by Route of Administration
  - 6.2.4.1.3. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Key market trends, growth factors and opportunities
  - 6.2.4.2.2. Market size and forecast, by Route of Administration
  - 6.2.4.2.3. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Key market trends, growth factors and opportunities
  - 6.2.4.3.2. Market size and forecast, by Route of Administration
  - 6.2.4.3.3. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Route of Administration
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Key market trends, growth factors and opportunities
  - 6.3.4.1.2. Market size and forecast, by Route of Administration
  - 6.3.4.1.3. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Key market trends, growth factors and opportunities
  - 6.3.4.2.2. Market size and forecast, by Route of Administration
  - 6.3.4.2.3. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Key market trends, growth factors and opportunities
  - 6.3.4.3.2. Market size and forecast, by Route of Administration
  - 6.3.4.3.3. Market size and forecast, by Application
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Key market trends, growth factors and opportunities
  - 6.3.4.4.2. Market size and forecast, by Route of Administration
  - 6.3.4.4.3. Market size and forecast, by Application
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Key market trends, growth factors and opportunities
  - 6.3.4.5.2. Market size and forecast, by Route of Administration
  - 6.3.4.5.3. Market size and forecast, by Application
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Key market trends, growth factors and opportunities
  - 6.3.4.6.2. Market size and forecast, by Route of Administration
  - 6.3.4.6.3. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Route of Administration
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Key market trends, growth factors and opportunities
  - 6.4.4.1.2. Market size and forecast, by Route of Administration
  - 6.4.4.1.3. Market size and forecast, by Application
  - 6.4.4.2. China
  - 6.4.4.2.1. Key market trends, growth factors and opportunities
  - 6.4.4.2.2. Market size and forecast, by Route of Administration
  - 6.4.4.2.3. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Key market trends, growth factors and opportunities
  - 6.4.4.3.2. Market size and forecast, by Route of Administration
  - 6.4.4.3.3. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Key market trends, growth factors and opportunities
  - 6.4.4.4.2. Market size and forecast, by Route of Administration
  - 6.4.4.4.3. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Key market trends, growth factors and opportunities
  - 6.4.4.5.2. Market size and forecast, by Route of Administration
  - 6.4.4.5.3. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Key market trends, growth factors and opportunities
  - 6.4.4.6.2. Market size and forecast, by Route of Administration
  - 6.4.4.6.3. Market size and forecast, by Application
6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Route of Administration
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Key market trends, growth factors and opportunities
  - 6.5.4.1.2. Market size and forecast, by Route of Administration
  - 6.5.4.1.3. Market size and forecast, by Application
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Key market trends, growth factors and opportunities
  - 6.5.4.2.2. Market size and forecast, by Route of Administration
  - 6.5.4.2.3. Market size and forecast, by Application
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Key market trends, growth factors and opportunities
  - 6.5.4.3.2. Market size and forecast, by Route of Administration
  - 6.5.4.3.3. Market size and forecast, by Application
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Key market trends, growth factors and opportunities
  - 6.5.4.4.2. Market size and forecast, by Route of Administration
  - 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. F. Hoffmann-La Roche Ltd.
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. GlaxoSmithKline plc
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Johnson & Johnson
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Merck & Co., Inc.
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Novartis AG
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Pfizer Inc.
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
8.7. Sanofi S.A.
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Bayer AG
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Cipla Ltd
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Amgen Inc.
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance

医薬品ドラッグデリバリー市場：投与経路別、用途別：世界の機会分析と産業予測、2023-2032年

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬品ドラッグデリバリー市場：投与経路別

第5章医薬品ドラッグデリバリー市場：用途別

第6章医薬品ドラッグデリバリー市場：地域別

第7章競合情勢

第8章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Route of Administration

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

医薬品ドラッグデリバリー市場：投与経路別、用途別：世界の機会分析と産業予測、2023-2032年

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 医薬品ドラッグデリバリー市場：投与経路別

第5章 医薬品ドラッグデリバリー市場：用途別

第6章 医薬品ドラッグデリバリー市場：地域別

第7章 競合情勢

第8章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Route of Administration

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬品ドラッグデリバリー市場：投与経路別

第5章医薬品ドラッグデリバリー市場：用途別

第6章医薬品ドラッグデリバリー市場：地域別

第7章競合情勢

第8章企業プロファイル